Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Health Care Equipment

Abbott LaboratoriesABT

Health Care Equipment · North Chicago, Illinois · In the S&P 500
Solid business
$106.20+1.56%After hours: $106.25 (+0.05%)At the close, 30 Oct · Prices from CNBC, may be delayed
▼ 14.7% over 1 year
Abbott Laboratories over 1 yearDaily close, $, to 30 Oct 2026
$100$120Nov2026MarMayJulSep$106.20$100$120NovMarJul$106.20
Source: Nasdaq daily closes
Market value$184B
Price to earnings39.4x
Forward P/E18.6x
Dividend yield2.37%
Year to date−15.2%
One year−14.7%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$82.56$130.59

The latest on Abbott Laboratories

Our stories first, then the headlines that could move it, newest first.

We haven't written about Abbott Laboratories yet. Follow it, and its first story will show under My stocks.

Quality and valuation

How Abbott Laboratories compares with other health care stocks. A description, not a recommendation.

Abbott Laboratories and 7 health care equipment peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: in line with its sector

An average business among health care companies, priced about in line with them.

Abbott Laboratories trades at 18.6 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +6.6% vs +7.8%
  • Keeps less of each sale (gross margin): 56.3% vs 65.3%
  • More profitable (operating margin): 17.1% vs 13.3%
  • Turns more of its sales into cash: 16.3% vs 15.9%
ABT trades at 18.6x forward earnings, below the sector medianForward p/e, Health Care Equipment peers
BSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xIDXX35.1xISRG37.5xSector median 19.1xBSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xEW29.3xIDXX35.1xISRG37.5xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 29.6x earnings, ABT is pricier than its average since May 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x40xAverage 25.4x2025202629.6x20x40xAverage 25.4x2025202629.6x
Source: Nasdaq prices; SEC filings

Financials

From Abbott Laboratories's SEC filings, through the quarter ending 31 Mar 2026. Hover or tap a bar for its value.

Revenue grew 7.8% from a year earlierQuarterly revenue, $bn, latest Q1 ’26
$0bn$5bn$10bnQ2 ’24Q4 ’24Q2 ’25$11.2bnQ1 ’26$0bn$5bn$10bnQ2 ’24Q4 ’24Q2 ’25$11.2bnQ1 ’26
Source: SEC filings
Growth sped up to +7.8% last quarterRevenue growth, year on year, %
0%2%4%6%Q2 ’24Q4 ’24Q2 ’257.8%Q1 ’260%5%Q2 ’24Q4 ’24Q2 ’257.8%Q1 ’26
Source: SEC filings
Operating margin was 12.0% last quarterOperating income as a share of revenue, %
0%5%10%15%Q2 ’24Q4 ’24Q2 ’2512.0%Q1 ’260%10%Q2 ’24Q4 ’24Q2 ’2512.0%Q1 ’26
Source: SEC filings
Free cash flow was $7.4 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0bn$1bn$2bnQ2 ’24Q4 ’24Q2 ’25$0.9bnQ1 ’26$0bn$1bn$2bnQ2 ’24Q4 ’24Q2 ’25$0.9bnQ1 ’26
Source: SEC filings
Last 12 monthsABTSector median
Revenue growth+6.6%+7.8%
Gross margin56.3%65.3%
Operating margin17.1%13.3%
Free cash flow margin16.3%15.9%
Price to earnings39.4x30.2x

Similar companies

Health Care Equipment, by market value.

CompanyPriceTodayYTDValue
ISRGIntuitive Surgical$432.01−3.73%−23.7%$150B
MDTMedtronic$96.54−0.59%+0.5%$123B
SYKStryker$291.86−6.38%−17.0%$112B
BSXBoston Scientific$41.98−1.66%−56.0%$60.84B
BDXBecton Dickinson$197.88−0.23%+27.4%$53.90B
EWEdwards Lifesciences$92.01−2.57%+7.9%$53.03B
IDXXIdexx Laboratories$551.21−4.30%−18.5%$43.42B
GEHCGE HealthCare$76.57+0.20%−6.6%$34.62B